Real-World Effectiveness and Safety of Tocilizumab in Refractory Rheumatoid Arthritis: A Retrospective Single-Centre Cohort Study of 44 Patients in Morocco

Background. Tocilizumab (TCZ), a monoclonal antibody directed against the interleukin-6 receptor, is used in rheumatoid arthritis (RA) after inadequate response or secondary loss of response to conventional synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Real-world data from North African cohorts remain scarce.